Your browser doesn't support javascript.
loading
Allogeneic peripheral blood stem cell transplantation in the treatment of hematologic malignancies / 中华血液学杂志
Chinese Journal of Hematology ; (12): 403-406, 2002.
Artigo em Chinês | WPRIM | ID: wpr-261424
ABSTRACT
<p><b>OBJECTIVE</b>To investigate the application of allogeneic peripheral blood stem cell transplantation (allo-PBSCT) in the treatment of hematologic malignancies.</p><p><b>METHODS</b>Between October 1995 and August 2001, fifty-one patients with hematologic malignancies (median age 34 years, range 5.5 approximately 52 years) received allo-PBSCT from HLA-identical (50) or 1-antigen mismatched sibling donors with conditioning regimens of TBI + CY or modified BU/CY2. Thirty-one patients were acute leukemia (AL) (15 in CR(1), 7 in CR(2) or greater, 10 in relapse including 2 relapse after allo-BMT and the other one never achieved remission); 12 chronic myeloid leukemia (CML) (CP 5, AP 2, BC 4 and relapse after allo-BMT 1); 7 MDS (RAEB 1, RAEB-T 1, AL secondary to MDS 5); Burkitt's lymphoma 1. A combination of cyclosporine and methotrexate was administered for GVHD prophylaxis.</p><p><b>RESULT</b>All patients were engrafted. The median time (range) to neutrophil >/= 0.5 x 10(9)/L and platelet >/= 20 x 10(9)/L was 14 (10 approximately 20) and 11 (7 approximately 45) days post-transplant, respectively. Grade II approximately IV acute GVHD occurred in 20/51 (39%) and grade III approximately IV aGVHD in 2 patients. Clinical chronic GVHD was diagnosed in 23 of 44 (52%) evaluable patients. Fourteen patients died 8 died of transplant related complications, 6 of relapse. Thirty-seven patients are alive with a median follow-up of 399 (75 approximately 2 176) days, and among them 34 are in continuous complete remission, the other 3 relapsed. The 2-year probability of overall survival, disease-free survival (DFS) and relapse is 64%, 61% and 24%, respectively.</p><p><b>CONCLUSION</b>Allogeneic PBSCT is safe for both donors and recipients, and results in a rapid and stable engraftment without increase in incidence or severity of acute GVHD.</p>
Assuntos
Texto completo: DisponíveL Índice: WPRIM (Pacífico Ocidental) Assunto principal: Terapêutica / Transplante Homólogo / Análise de Sobrevida / Doença Aguda / Taxa de Sobrevida / Seguimentos / Mortalidade / Resultado do Tratamento / Transplante de Células-Tronco Hematopoéticas / Neoplasias Hematológicas Tipo de estudo: Estudo observacional / Estudo prognóstico Limite: Adolescente / Adulto / Criança / Feminino / Humanos / Masculino Idioma: Chinês Revista: Chinese Journal of Hematology Ano de publicação: 2002 Tipo de documento: Artigo

Similares

MEDLINE

...
LILACS

LIS

Texto completo: DisponíveL Índice: WPRIM (Pacífico Ocidental) Assunto principal: Terapêutica / Transplante Homólogo / Análise de Sobrevida / Doença Aguda / Taxa de Sobrevida / Seguimentos / Mortalidade / Resultado do Tratamento / Transplante de Células-Tronco Hematopoéticas / Neoplasias Hematológicas Tipo de estudo: Estudo observacional / Estudo prognóstico Limite: Adolescente / Adulto / Criança / Feminino / Humanos / Masculino Idioma: Chinês Revista: Chinese Journal of Hematology Ano de publicação: 2002 Tipo de documento: Artigo